$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

$itci Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000119312514394322 Filed on November 03, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$65.86K	$124.4K	$668.0K
YoY Change	-92.04%	-81.37%	76.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.720M	$2.580M	$1.300M
YoY Change	36.26%	98.46%	62.5%
% of Gross Profit
Research & Development	$11.64M	$4.046M	$4.158M
YoY Change	89.89%	-2.68%	131.32%
% of Gross Profit
Depreciation & Amortization	$10.00K	$6.409K	$4.729K
YoY Change		35.53%	-52.71%
% of Gross Profit
Operating Expenses	$15.36M	$4.046M	$4.158M
YoY Change	73.36%	-2.68%	131.32%
Operating Profit		-$6.504M	-$4.785M
YoY Change		35.91%	115.4%
Interest Expense	$100.0K		$131.9K
YoY Change	900.0%		1218.88%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$15.20M	-$6.420M	-$4.910M
YoY Change	89.53%	30.75%	122.17%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$15.20M	-$6.416M	-$4.912M
YoY Change	89.02%	30.62%	121.24%
Net Earnings / Revenue	-23077.24%	-5156.58%	-735.32%
Basic Earnings Per Share			-$0.42
Diluted Earnings Per Share	-$516.3K	-$218.5K	-$0.42
COMMON SHARES
Basic Shares Outstanding	29.40M shares	29.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$129.6M	$136.0M	$46.10M
YoY Change	248.39%	195.01%
Cash & Equivalents	$61.33M	$68.92M	$44.07M
Short-Term Investments	$68.30M	$67.10M	$2.000M
Other Short-Term Assets	$1.300M	$1.400M	$800.0K
YoY Change	62.5%	75.0%
Inventory
Prepaid Expenses
Receivables	$51.60K	$124.4K	$251.3K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$131.0M	$137.5M	$47.13M
YoY Change	242.45%	191.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$54.55K	$57.44K	$75.70K
YoY Change	-20.09%	-24.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$70.94K	$70.94K	$130.8K
YoY Change	-46.07%	-45.74%
Total Long-Term Assets	$125.5K	$128.4K	$206.5K
YoY Change	-37.2%	-37.82%
TOTAL ASSETS
Total Short-Term Assets	$131.0M	$137.5M	$47.13M
Total Long-Term Assets	$125.5K	$128.4K	$206.5K
Total Assets	$131.1M	$137.6M	$47.34M
YoY Change	241.0%	190.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.053M	$503.9K	$4.027M
YoY Change	-39.54%	-87.49%
Accrued Expenses	$8.500M	$3.100M	$3.300M
YoY Change	150.0%	-6.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.56M	$3.578M	$7.775M
YoY Change	54.48%	-53.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.56M	$3.578M	$7.775M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$10.56M	$3.600M	$7.800M
YoY Change	55.25%	-53.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$88.26M	-$73.06M	-$49.52M
YoY Change	53.32%	47.52%
Common Stock	$208.9M	$2.940K	$2.213K
YoY Change	9427485.51%	32.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$120.6M	$134.0M	$39.56M
YoY Change
Total Liabilities & Shareholders Equity	$131.1M	$137.6M	$47.34M
YoY Change	241.0%	190.71%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$15.20M	-$6.416M	-$4.912M
YoY Change	89.02%	30.62%	121.24%
Depreciation, Depletion And Amortization	$10.00K	$6.409K	$4.729K
YoY Change		35.53%	-52.71%
Cash From Operating Activities	-$6.210M	-$4.420M	-$4.760M
YoY Change	-28.04%	-7.14%	-14.85%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$20.00K
YoY Change		-100.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	-$1.440M	-$17.84M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$1.440M	-$17.84M	-$20.00K
YoY Change		89100.0%	-101.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	70.00K	30.00K	40.52M
YoY Change	-124.14%	-99.93%	405100.0%
NET CHANGE
Cash From Operating Activities	-6.210M	-4.420M	-4.760M
Cash From Investing Activities	-1.440M	-17.84M	-20.00K
Cash From Financing Activities	70.00K	30.00K	40.52M
Net Change In Cash	-7.580M	-22.23M	35.74M
YoY Change	-15.02%	-162.2%	-1030.73%
FREE CASH FLOW
Cash From Operating Activities	-$6.210M	-$4.420M	-$4.760M
Capital Expenditures	$0.00	$0.00	-$20.00K
Free Cash Flow	-$6.210M	-$4.420M	-$4.740M
YoY Change	-28.04%	-6.75%	-15.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1087529	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.00
CY2014Q3	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	1.00	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.56
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2232826	shares
CY2014Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3243886
CY2014Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2143756
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3577601
CY2014Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	2940
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-67389
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	503882
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73056827
CY2014Q1	us-gaap	Share Price SharePrice	17.50
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29397169	shares
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44072012
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29397169	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29397169	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2232826	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.56
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	134031637
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137609238
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	70944
CY2014Q3	us-gaap	Assets Current AssetsCurrent	137480854
CY2013Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3232003
CY2013Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2611091
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207152913
CY2014Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000
CY2014Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	929963
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68915333
CY2014Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	10300000
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57440
CY2014Q3	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	116350000
CY2014Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	67066729
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1374378
CY2014Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	70000
CY2014Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3301326
CY2014Q3	us-gaap	Assets Assets	137609238
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	124414
CY2014Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	67135000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15645528
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22159446	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22159446	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.98
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1400125	shares
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6834037
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	2216
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3395067
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57564497
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	31615275
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38449312
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89177556
CY2013Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	827879
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35150924
CY2013Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	0
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	68272
CY2013Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	6000000
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	2000000
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	762243
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3300275
CY2013Q4	us-gaap	Assets Assets	38449312
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	336318
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2000000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	131555
CY2013Q4	us-gaap	Assets Current AssetsCurrent	38249485
	us-gaap	Net Income Loss NetIncomeLoss	-18827388
	us-gaap	Investment Income Interest InvestmentIncomeInterest	11589
	us-gaap	Interest Paid InterestPaid	3317
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49138
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1249992
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7063300	shares
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	115400000
CY2014Q1	itci	Share Issued During Period Shares Underwriters New Issues ShareIssuedDuringPeriodSharesUnderwritersNewIssues	921300	shares
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13963457
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15616835	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.21
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3445315
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	617586
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18234017
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18827388
	us-gaap	Income Taxes Paid IncomeTaxesPaid	13437
	us-gaap	Revenues Revenues	1909471
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33255
	us-gaap	Interest Expense InterestExpense	604960
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16897903
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	28426484
	us-gaap	Depreciation Depreciation	15821
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	40923196
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43841850
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2398611
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1466745
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	20143488
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	316827
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	100000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1500000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3245585
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3985489
	us-gaap	Share Based Compensation ShareBasedCompensation	282450
	itci	Proceeds From Common Stock Subscribed ProceedsFromCommonStockSubscribed	109834
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022	pure
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Deferred Revenue</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash received as prepayment on future services is deferred and recognized as revenue as the services are performed. The Company must remit interest on any deferred revenue related to a governmental agency. As of September 30, 2014 and December 31, 2013, no interest was due as the Company did not have any deferred revenue.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	988000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.67
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	Intra-Cellular Therapies, Inc.
	dei	Trading Symbol TradingSymbol	ITCI
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16600815
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M18D
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28386794	shares
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.30
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M6D
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	7500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.64
	dei	Entity Central Index Key EntityCentralIndexKey	0001567514
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.80	pure
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash equivalents are held with major financial institutions in the United States. Certificates of deposit held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> </div>
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	147799	shares
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	748538
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-144017
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	92272925
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-67389
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	551524
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15689653
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15559719
	us-gaap	Income Taxes Paid IncomeTaxesPaid	40557
	us-gaap	Revenues Revenues	511439
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8324
	us-gaap	Net Income Loss NetIncomeLoss	-15492330
	us-gaap	Investment Income Interest InvestmentIncomeInterest	204396
	us-gaap	Interest Paid InterestPaid	7073
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-211904
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-6415507
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	88099
CY2014Q3	us-gaap	Interest Expense InterestExpense
	us-gaap	Depreciation Depreciation	19156
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	115651683
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	116191285
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-365251
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
	us-gaap	Interest Expense InterestExpense	7073
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9585336
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	33764409
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	131538
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-65286459
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	16201092
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	99103
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	26994790
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6615756
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2891185
	us-gaap	Share Based Compensation ShareBasedCompensation	2192860
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
	itci	Percentage Of Dividend Rate PercentageOfDividendRate	0.00	pure
	itci	Proceeds From Common Stock Subscribed ProceedsFromCommonStockSubscribed	109833
	itci	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm	P8M12D
	itci	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2	P9Y8M12D
	itci	Available For Sale Securities Maturity Period AvailableForSaleSecuritiesMaturityPeriod	More than three months
	itci	Maturity Period Of Liquid Investments To Be Considered As Cash Equivalents MaturityPeriodOfLiquidInvestmentsToBeConsideredAsCashEquivalents	Three months or less
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17527774	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4785358
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4911620
CY2013Q3	us-gaap	Revenues Revenues	667955
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-4911620
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5626
CY2013Q3	us-gaap	Interest Expense InterestExpense	131888
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4157742
CY2013Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5453313
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1295571
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	119217
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29379156	shares
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2014Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-19640
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6503606
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6435147
CY2014Q3	us-gaap	Revenues Revenues	124414
CY2014Q3	us-gaap	Depreciation Depreciation	6409
CY2014Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	6628020
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4046335
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2581685
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1702645

Files In Submission

Name	View Source	Status
0001193125-14-394322-index-headers.html	Edgar Link	pending
0001193125-14-394322-index.html	Edgar Link	pending
0001193125-14-394322.txt	Edgar Link	pending
0001193125-14-394322-xbrl.zip	Edgar Link	pending
d802324d10q.htm	Edgar Link	pending
d802324dex101.htm	Edgar Link	pending
d802324dex311.htm	Edgar Link	pending
d802324dex312.htm	Edgar Link	pending
d802324dex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g802324logo.jpg	Edgar Link	pending
itci-20140930.xml	Edgar Link	completed
itci-20140930.xsd	Edgar Link	pending
itci-20140930_cal.xml	Edgar Link	unprocessable
itci-20140930_def.xml	Edgar Link	unprocessable
itci-20140930_lab.xml	Edgar Link	unprocessable
itci-20140930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

2014 Q4 Form 10-Q Financial Statement

#000119312514394322 Filed on November 03, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI Intra-Cellular Therapies, Inc. Stock $itci

2014 Q4 Form 10-Q Financial Statement

#000119312514394322 Filed on November 03, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci